Programme

Pre-Conference Course

OSTEOPOROSIS: ESSENTIALS OF DENSITOMETRY, DIAGNOSIS AND MANAGEMENT COURSE
Wed, November 28
13.30 - 17.10
13.30
Welcome and Opening Remarks — N. Pocock
13.40
Overview of Osteoporosis — N. Pocock
14.30
Bone Measurement Device Operating Principles — S. Baldwin
15.20
Coffee Break
15.40
X-Ray Science, Radiation Safety and Quality Assurance — N. Pocock
16.20
Clinical Evaluation of Bone Health
Thu, November 29
08.00 - 17.00
08.00
Use of Bone Densitometry for the Diagnosis of Osteoporosis — J. Center
08.50
Fracture Risk Assessment — S. Baldwin
09.40
Monitoring Treatment of Osteoporosis — J. Wark
10.30
Coffee Break
10.50
Clinical Management Part 1: Non-Pharmacologic, Estrogen & SERM Treatment
11.40
Clinical Management Part 2: Pharmacological Treatment Continued — J. Center
12.30
Lunch Break
13.30
Clinical Management Part 3: Further Pharmacologic Treatment Considerations — M. Chandran
14.20
Principles of DXA Scan Interpretation — N. Pocock
15.10
Coffee Break
15.30
Principles of Reporting DXA Scans — M. Chandran
16.20
Cases for Discussion — N. Pocock

Conference

Thu, November 29
17.30
19.30
OPENING CEREMONY
  • Welcome — C. Cooper, J. A. Kanis & M. Chandran
  • Best clinical papers of 2018 — R. Rizzoli
  • Inclusion of diversity in science — S. Lee Brennan
  • Local CNS lecture — Osteoporosis Australia
  • Osteoporosis, global challenge, local impacts — L. March
  • Conclusion
Fri, November 30
08.30
18.00
EXHIBITION AREA OPEN
08.30
PLENARY SESSION I
Improving the identification of high risk patients
Chair: J. A. Kanis & E. Seeman
  • Can FRAX be improved — J. A. Kanis
  • CtF/FLS: what have we achieved — C. Cooper
  • New imaging modalities — S. Ferrari
10.00
POSTER VIEWING AND EXHIBITION
10.00
INDUSTRY-SPONSORED SATELLITE SYMPOSIUM
11.00
PLENARY SESSION II
Similarities and differences in fracture risk and treatments respone: Asia vs West (IOF-OA session)
Chair: C. Cooper (IOF) & G. Liubomirsky (OA)
  • BMD and other parameters of bone in Asia vs West — K. Sanders
  • FRAX: intervention threshold in Asia vs West — E. Lau
  • Response to osteoporosis treatment: is it the same in Asian and Caucasian (benefit/risk including AFF) — P. Ebeling
12.30
INDUSTRY-SPONSORED LUNCH SYMPOSIUM
13.30
MEET-THE-EXPERT SESSIONS
  • Recent Fracture: when and how to treat osteoporosis — J.-K. Lee
  • Chronic renal failure: how to assess and manage bone fragility? — P. Ebeling
  • Vitamin D: which & how much? — A. Mithal
  • Protein intake and supplement in fracture patient — R. Rizzoli
14.15
PLENARY SESSION III
Quality of life in musculoskeletal diseases - ESCEO symposium
Chair: R. Rizzoli & E. Biver
  • Introduction — O. Bruyère
  • Assessment of quality of life in osteoporosis — J.-M. Kaufman
  • Assessment of quality of life in osteoarthritis — N. Arden
  • Assessment of quality of life in sarcopenia — F. Buckinx
  • Discussion — J.-Y. Reginster
  • Conclusion — J.-Y. Reginster
15.45
IOF-APOA JOINT SESSION
  • J. K. Lee
  • D. Choon
  • Questions & Answers
16.30
18.00
CNS ROUNDTABLE
Mapping calcium intake
Chair: B. Dawson-Hughes
  • Dietary calcium intake worldwide (Ca map) — B. Dawson-Hughes
  • Consequences of low calcium intake in the Asia Pacific region — R. Rizzoli
  • Calcium supplements and fracture prevention — A. Mithal
  • Calcium intake and its implication in China — Wei-bo Xia
  • Roundtable: Potential strategies to improve calcium intake - What is feasible within the low intake countries
Sat, December 1
08.00
17.00
EXHIBITION AREA OPEN
08.15
MEET-THE-EXPERT SESSIONS
  • Falls prevention: is it possible — W. L. Hsu
  • Bone loss in early menopause: to treat or not?
  • Genetic markers of bone fragility: what have we learned — E. Duncan
  • Can we trust bone turnover markers to improve fracture assessment — H. Morris
09.00
PLENARY SESSION V
Assessment and management of bone fragility beyond idiopathic osteoporosis (IOF-ANZBMS session)
Chair: S. Ferrari (IOF) & P. Croucher (ANZBMS)
  • Fracture prevention in cancer patients — E. Biver
  • Fracture prevention in diabetes patients — M. Chandran
  • When to suspect a genetic disorder? — J. Eisman
10.30
POSTER VIEWING AND EXHIBITION
11.00
PLENARY SESSION VI
New insights in the management of knee osteoarthritis - ESCEO Symposium
Chair: C. Cooper & F. Cicuttini
  • Welcome — C. Cooper
  • The 2014-2016 ESCEO algorithm for the management of knee osteoarthritis — O. Bruyère
  • New insights on the safety of anti-osteoarthritis medications — E. Dennison
  • New clinical evidence supporting the use of SYSADOAs as a first-line background treatment in knee osteoarthritis — J.-Y. Reginster
  • Update of the 2014-2016 ESCEO algorithm for the managment of knee osteoarthritis — C. Cooper
  • Discussion — C. Cooper
  • Conclusion — J.-Y. Reginster
12.30
INDUSTRY-SPONSORED SATELLITE SYMPOSIUM
13.30
IOF-OA-ANZBMS JOINT SESSION
  • Excercice and osteoporosis — B. Beck
  • Monetary cost of osteoporosis — J. A. Kanis
  • Morbidity and mortality of osteoporosis — J. Center
14.15
YOUNG INVESTIGATOR AWARDS SESSION
14.15
MEET-THE-EXPERT SESSIONS
  • Osteosarcopenia — G. Duque
  • Glucocorticoid osteoporosis — E. Dennison
  • Assessment of physical strength and performance — F. Buckinx
15.15
16.30
PLENARY SESSION VII
Osteoporosis treatment: update
  • Benefit/Risk of long term treatment — S. Ferrari
  • Fracture risk off therapy — E. Dennison
  • Closing the gap in the treatment of patients at imminent risk of fracture: role of the new anabolic agents — J.-Y. Reginster